Perlmutter Cancer Center

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Endometrial
  Sqcc Of Vagina Or Vulva
• Age: Between 18 years - 99 years
• Gender: Female

• Other Inclusion Criteria:
  

  1.  Patients with microsatellite instability high endometrial cancer who have progressed on or after at least 1, but no more than 2 lines of anti-cancer therapy (of which, at least 1 must be a platinum-based therapy) known to provide a clinical benefit for advanced or metastatic disease

   

  2.  Patients with microsatellite stable endometrial cancer who have progressed on or after at least 1, but no more than 2 lines of anti-cancer therapy known to provide a clinical benefit for advanced or metastatic disease

   

  3.  All endometrial cancer histologies are allowed, except uterine sarcomas and carcinosarcomas

   

  4.  Presence of at least one measurable lesion on baseline scan confirmed by central radiology review

  
  

You may not be eligible for this study if the following are true:

• 1.  Patients who received prior therapy with an anti-programmed death-1 (anti-PD-1), anti-PD-1-ligand-1, or anti-PD-1 ligand-2 agent.

   

  2.  Patient has a known hypersensitivity to TSR-042 components or excipients

   

  3.  Patient has a known additional malignancy that progressed or required active treatment within the last 2 years.

   

  4.  Patient has known uncontrolled central nervous system metastases and/or carcinomatous meningitis; history of interstitial lung disease; known history of HIV, or known active hepatitis B or hepatitis C